| Basics |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics Inc is a clinical stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
|
| IPO Date: |
April 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$166.87M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 3.28%
|
| Avg Daily Range (30 D): |
$0.02 | 4.98%
|
| Avg Daily Range (90 D): |
$0.02 | 4.37%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.24M |
| Avg Daily Volume (30 D): |
6.96M |
| Avg Daily Volume (90 D): |
5.53M |
| Trade Size |
| Avg Trade Size (Sh.): |
225 |
| Avg Trade Size (Sh.) (30 D): |
562 |
| Avg Trade Size (Sh.) (90 D): |
595 |
| Institutional Trades |
| Total Inst.Trades: |
2,787 |
| Avg Inst. Trade: |
$1.51M |
| Avg Inst. Trade (30 D): |
$2.08M |
| Avg Inst. Trade (90 D): |
$2.08M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$2.08M |
| Avg Closing Trade (90 D): |
$2.08M |
| Avg Closing Volume: |
214.13K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.44
|
$-.11
|
$-.08
|
|
Diluted EPS
|
$-.44
|
$-.11
|
$-.08
|
|
Revenue
|
$ 32.88M
|
$ .58M
|
$ 18.31M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -108.91M
|
$ -34.93M
|
$ -19.99M
|
|
Operating Income / Loss
|
$ -109.03M
|
$ -35.55M
|
$ -17.86M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -10.17M
|
$ -9.32M
|
$ -2.3M
|
|
PE Ratio
|
|
|
|
|
|
|
